Scott Shannon1, Nicole Lewis2, Heather Lee3, Shannon Hughes4. 1. Department of Psychiatry, University of Colorado, Denver. 2. Department of Naturopathic Medicine, Wholeness Center, Fort Collins, CO. 3. North Range Behavioral Health, Greeley, CO. 4. School of Social Work, Colorado State University College of Health and Human Sciences, Fort Collins.
Abstract
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature. OBJECTIVE: To determine whether CBD helps improve sleep and/or anxiety in a clinical population. DESIGN: A large retrospective case series at a psychiatric clinic involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment. The retrospective chart review included monthly documentation of anxiety and sleep quality in 103 adult patients. MAIN OUTCOME MEASURES: Sleep and anxiety scores, using validated instruments, at baseline and after CBD treatment. RESULTS: The final sample consisted of 72 adults presenting with primary concerns of anxiety (n = 47) or poor sleep (n = 25). Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time. In this chart review, CBD was well tolerated in all but 3 patients. CONCLUSION: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature. OBJECTIVE: To determine whether CBD helps improve sleep and/or anxiety in a clinical population. DESIGN: A large retrospective case series at a psychiatric clinic involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment. The retrospective chart review included monthly documentation of anxiety and sleep quality in 103 adult patients. MAIN OUTCOME MEASURES: Sleep and anxiety scores, using validated instruments, at baseline and after CBD treatment. RESULTS: The final sample consisted of 72 adults presenting with primary concerns of anxiety (n = 47) or poor sleep (n = 25). Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time. In this chart review, CBD was well tolerated in all but 3 patients. CONCLUSION:Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.
Authors: Johannes Fuss; Jörg Steinle; Laura Bindila; Matthias K Auer; Hartmut Kirchherr; Beat Lutz; Peter Gass Journal: Proc Natl Acad Sci U S A Date: 2015-10-05 Impact factor: 11.205
Authors: D I Abrams; C A Jay; S B Shade; H Vizoso; H Reda; S Press; M E Kelly; M C Rowbotham; K L Petersen Journal: Neurology Date: 2007-02-13 Impact factor: 9.910
Authors: Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa Journal: Neuropsychopharmacology Date: 2011-02-09 Impact factor: 7.853
Authors: Cerina Lee; Jessica M Round; Scott Klarenbach; John G Hanlon; Elaine Hyshka; Jason R B Dyck; Dean T Eurich Journal: Harm Reduct J Date: 2021-06-08
Authors: Ayobami Salami; Jorma Heikkinen; Laura Tomppo; Marko Hyttinen; Timo Kekäläinen; Janne Jänis; Jouko Vepsäläinen; Reijo Lappalainen Journal: Molecules Date: 2021-05-25 Impact factor: 4.411